Business Wire

WORLD-GOVERNMENT-SUMMIT

5.5.2021 13:47:13 CEST | Business Wire | Press release

Share
Nearly 50% of Pandemic Costs Will Fall on Advanced Economies, World Government Summit Report Finds

A seminal report launched by the World Government Summit Organization (WGS) which highlights 21 critical priorities within five focus areas offers a source of direction for governments as they tackle post-COVID-19 recovery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005573/en/

Wealthier economies will shoulder almost half the cost of the COVID-19 crisis, which could reach up to US$3.8 trillion in 2021, the report finds. That, even if developed economies can vaccinate their entire populace and developing economies can reach a 50 percent vaccination rate.

The report says mental health wellness, climate change and women’s empowerment are central concerns that will exacerbate if governments do not rebuild in a holistic, proactive manner.

His Excellency Mohammad Abdullah Al Gergawi, UAE Minister of Cabinet Affairs and Chairman of the World Government Summit Organization, said: “2020 will be remembered by history as the year of great disruption. While the world was woefully unprepared for the voracity of the virus, 2021 needs to be the year that defines humanity’s future and reshape societies to become stronger and more resilient.”

He added: “With great change comes great opportunity. Valuable lessons emerged over the past year, which we must heed as we recover. Our individual and collective actions as nations have important consequences not only for us, but for our children and the many generations to come after them: we must all be accountable to ourselves and each other.”

With governments’ focus trained on the pandemic over the last 18 months, underlying societal issues such as the mental health and climate crises have exacerbated, and could become as problematic as the public health emergency if leaders do not adapt their thinking, the report suggests.

The 21 priorities outlined by the report are broken down into five sections:

These five focus areas are:

  1. Reimagining and Reinforcing Key Public Institutions
  2. Competing in a Transformed Economy
  3. Navigating a Transformed Geo-Technical Order
  4. Repairing the Social Fabric
  5. Securing the Future

Please download the full report here :

About WGS:

The World Government Summit Organization is a global, neutral, non-profit organization dedicated to shaping the future of governments. The Summit, in its various activities, explores the agenda of the next generation of governments, focusing on harnessing innovation and technology to solve universal challenges facing humanity.

The World Government Summit Organization operates at the intersection of government and innovation. It functions as a knowledge exchange platform that convenes leaders in the public and private sectors to collaborate with world-renowned experts in creating positive impact for citizens around the world. Including initiatives and events held throughout the year, the World Government Summit holds a flagship annual gathering in Dubai.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye